UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SCHEDULE 13D
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO
RULES 13d-1(a) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(a)
(Amendment No. )1
C/o Advent International Corporation, 75 State Street, 29th Floor
Boston, MA 02109
Receive Notices and Communications)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box:.o
Note:Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.See Rule 13d-7(b) for other parties to whom copies are to be sent.
(Continued on following pages)
(Page 1 of 20 pages)
1 The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. | 00767E102 | Schedule 13D | Page | 2 | of | 20 |
1 | NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY) Advent International Corporation | ||||||||||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* | ||||||||||
(a) þ | |||||||||||
(b) o | |||||||||||
3 | SEC USE ONLY | ||||||||||
4 | SOURCE OF FUNDS | ||||||||||
WC | |||||||||||
5 | CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) | ||||||||||
o | |||||||||||
6 | CITIZENSHIP OR PLACE OF ORGANIZATION | ||||||||||
Delaware | |||||||||||
7 | SOLE VOTING POWER | ||||||||||
NUMBER OF | 2,786,110 | ||||||||||
SHARES | 8 | SHARED VOTING POWER | |||||||||
BENEFICIALLY | |||||||||||
OWNED BY | None | ||||||||||
EACH | 9 | SOLE DISPOSITIVE POWER | |||||||||
REPORTING | |||||||||||
PERSON | 2,786,110 | ||||||||||
WITH | 10 | SHARED DISPOSITIVE POWER | |||||||||
None | |||||||||||
11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | ||||||||||
2,786,110 | |||||||||||
12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ||||||||||
o | |||||||||||
13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) | ||||||||||
15.83% | |||||||||||
14 | TYPE OF REPORTING PERSON* | ||||||||||
CO, IA |
CUSIP No. | 00767E102 | Schedule 13D | Page | 3 | of | 20 |
1 | NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY) Advent International LLC | ||||||||||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* | ||||||||||
(a) þ | |||||||||||
(b) o | |||||||||||
3 | SEC USE ONLY | ||||||||||
4 | SOURCE OF FUNDS | ||||||||||
WC | |||||||||||
5 | CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) | ||||||||||
o | |||||||||||
6 | CITIZENSHIP OR PLACE OF ORGANIZATION | ||||||||||
Massachusetts | |||||||||||
7 | SOLE VOTING POWER | ||||||||||
NUMBER OF | 2,755,374 | ||||||||||
SHARES | 8 | SHARED VOTING POWER | |||||||||
BENEFICIALLY | |||||||||||
OWNED BY | None | ||||||||||
EACH | 9 | SOLE DISPOSITIVE POWER | |||||||||
REPORTING | |||||||||||
PERSON | 2,755,374 | ||||||||||
WITH | 10 | SHARED DISPOSITIVE POWER | |||||||||
None | |||||||||||
11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | ||||||||||
2,755,374 | |||||||||||
12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ||||||||||
o | |||||||||||
13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) | ||||||||||
15.65% | |||||||||||
14 | TYPE OF REPORTING PERSON* | ||||||||||
PN |
CUSIP No. | 00767E102 | Schedule 13D | Page | 4 | of | 20 |
1 | NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY) AHLS III GP Limited Partnership | ||||||||||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* | ||||||||||
(a) þ | |||||||||||
(b) o | |||||||||||
3 | SEC USE ONLY | ||||||||||
4 | SOURCE OF FUNDS | ||||||||||
WC | |||||||||||
5 | CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) | ||||||||||
o | |||||||||||
6 | CITIZENSHIP OR PLACE OF ORGANIZATION | ||||||||||
Massachusetts | |||||||||||
7 | SOLE VOTING POWER | ||||||||||
NUMBER OF | 2,755,374 | ||||||||||
SHARES | 8 | SHARED VOTING POWER | |||||||||
BENEFICIALLY | |||||||||||
OWNED BY | None | ||||||||||
EACH | 9 | SOLE DISPOSITIVE POWER | |||||||||
REPORTING | |||||||||||
PERSON | 2,755,374 | ||||||||||
WITH | 10 | SHARED DISPOSITIVE POWER | |||||||||
None | |||||||||||
11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | ||||||||||
2,755,374 | |||||||||||
12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ||||||||||
o | |||||||||||
13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) | ||||||||||
15.65% | |||||||||||
14 | TYPE OF REPORTING PERSON* | ||||||||||
PN |
CUSIP No. | 00767E102 | Schedule 13D | Page | 5 | of | 20 |
1 | NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY) Advent Healthcare and Life Sciences III Limited Partnership | ||||||||||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* | ||||||||||
(a) þ | |||||||||||
(b) o | |||||||||||
3 | SEC USE ONLY | ||||||||||
4 | SOURCE OF FUNDS | ||||||||||
WC | |||||||||||
5 | CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) | ||||||||||
o | |||||||||||
6 | CITIZENSHIP OR PLACE OF ORGANIZATION | ||||||||||
Delaware | |||||||||||
7 | SOLE VOTING POWER | ||||||||||
NUMBER OF | 1,116,597 | ||||||||||
SHARES | 8 | SHARED VOTING POWER | |||||||||
BENEFICIALLY | |||||||||||
OWNED BY | None | ||||||||||
EACH | 9 | SOLE DISPOSITIVE POWER | |||||||||
REPORTING | |||||||||||
PERSON | 1,116,597 | ||||||||||
WITH | 10 | SHARED DISPOSITIVE POWER | |||||||||
None | |||||||||||
11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | ||||||||||
1,116,597 | |||||||||||
12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ||||||||||
o | |||||||||||
13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) | ||||||||||
6.34% | |||||||||||
14 | TYPE OF REPORTING PERSON* | ||||||||||
PN |
CUSIP No. | 00767E102 | Schedule 13D | Page | 6 | of | 20 |
1 | NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY) Advent Healthcare and Life Sciences III A Limited Partnership | ||||||||||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* | ||||||||||
(a) þ | |||||||||||
(b) o | |||||||||||
3 | SEC USE ONLY | ||||||||||
4 | SOURCE OF FUNDS | ||||||||||
WC | |||||||||||
5 | CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) | ||||||||||
o | |||||||||||
6 | CITIZENSHIP OR PLACE OF ORGANIZATION | ||||||||||
Delaware | |||||||||||
7 | SOLE VOTING POWER | ||||||||||
NUMBER OF | 1,638,777 | ||||||||||
SHARES | 8 | SHARED VOTING POWER | |||||||||
BENEFICIALLY | |||||||||||
OWNED BY | None | ||||||||||
EACH | 9 | SOLE DISPOSITIVE POWER | |||||||||
REPORTING | |||||||||||
PERSON | 1,638,777 | ||||||||||
WITH | 10 | SHARED DISPOSITIVE POWER | |||||||||
None | |||||||||||
11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | ||||||||||
1,638,777 | |||||||||||
12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ||||||||||
o | |||||||||||
13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) | ||||||||||
9.31% | |||||||||||
14 | TYPE OF REPORTING PERSON* | ||||||||||
PN |
CUSIP No. | 00767E102 | Schedule 13D | Page | 7 | of | 20 |
1 | NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY) Advent Partners HLS III Limited Partnership | ||||||||||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* | ||||||||||
(a) þ | |||||||||||
(b) o | |||||||||||
3 | SEC USE ONLY | ||||||||||
4 | SOURCE OF FUNDS | ||||||||||
WC | |||||||||||
5 | CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) | ||||||||||
o | |||||||||||
6 | CITIZENSHIP OR PLACE OF ORGANIZATION | ||||||||||
Delaware | |||||||||||
7 | SOLE VOTING POWER | ||||||||||
NUMBER OF | 30,736 | ||||||||||
SHARES | 8 | SHARED VOTING POWER | |||||||||
BENEFICIALLY | |||||||||||
OWNED BY | None | ||||||||||
EACH | 9 | SOLE DISPOSITIVE POWER | |||||||||
REPORTING | |||||||||||
PERSON | 30,736 | ||||||||||
WITH | 10 | SHARED DISPOSITIVE POWER | |||||||||
None | |||||||||||
11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | ||||||||||
30,736 | |||||||||||
12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ||||||||||
o | |||||||||||
13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) | ||||||||||
0.17% | |||||||||||
14 | TYPE OF REPORTING PERSON* | ||||||||||
PN |
CUSIP No. | 00767E102 | Schedule 13D | Page | 8 | of | 20 |
Item 1. | Security and Issuer |
Item 2. | Identity and Background |
CUSIP No. | 00767E102 | Schedule 13D | Page | 9 | of | 20 |
Item 3. | Source and Amount of Funds or Other Consideration. |
CUSIP No. | 00767E102 | Schedule 13D | Page | 10 | of | 20 |
Item 4. | Purpose of Transaction. |
CUSIP No. | 00767E102 | Schedule 13D | Page | 11 | of | 20 |
Item 5. | Interest in Securities of the Issuer. |
CUSIP No. | 00767E102 | Schedule 13D | Page | 12 | of | 20 |
Number of | ||||||||||||
Shares | ||||||||||||
Number of | Percentage | Purchased | ||||||||||
Shares | of Common | in | ||||||||||
Reporting | Beneficially | Stock | Past 60 | |||||||||
Person | Owned | Outstanding | Days | |||||||||
Advent International Corporation (1)(2)(3) | 2,786,110 | 15.83 | % | 263,158 | ||||||||
Advent International LLC (1) (2) | 2,755,374 | 15.65 | % | 260,263 | ||||||||
AHLS III GP Limited Partnership (1) (2) | 2,755,374 | 15.65 | % | 260,263 | ||||||||
Advent Healthcare and Life Sciences III Limited Partnership (2) | 1,116,597 | 6.34 | % | 105,473 | ||||||||
Advent Healthcare and Life Sciences III A Limited Partnership (2) | 1,638,777 | 9.31 | % | 154,790 | ||||||||
Advent Partners HLS III Limited Partnership(3) | 30,736 | 0.17 | % | 2,895 | ||||||||
Total Group | 2,786,110 | 15.83 | % | 263,158 |
(1) | Advent International Corporation (“AIC”) is the Manager of Advent International LLC (“AI LLC”) which in turn is the General Partner AHLS III GP (“AHLS III GP”) Limited Partnership which in turn is the General Partner of the indicated Reporting Persons. As such, AIC has the sole power to vote and dispose of the securities owned by the indicated Reporting Persons. The beneficial ownership of AIC, AI LLC and AHLS III GP derive from such power. | |
(2) | Advent International Corporation (“AIC”) is the Manager of Advent International LLC (“AI LLC”) which in turn is the General Partner |
CUSIP No. | 00767E102 | Schedule 13D | Page | 13 | of | 20 |
of AHLS III GP Limited Partnership (“AHLS III GP”) which in turn is the General Partner of the indicated Reporting Persons. As such, AIC has the sole power to vote and dispose of the securities of Advent Healthcare and Life Sciences III Limited Partnership and Advent Healthcare and Life Sciences III A Limited Partnership. The beneficial ownership of AIC, AI LLC and AHLS III GP derive from such power. | ||
(3) | Advent International Corporation (“AIC”) is the General Partner the indicated Reporting Persons. As such, AIC has the sole power to vote and dispose of the securities of Advent Partners HLS III Limited Partnership. The beneficial ownership of AIC derives from such power. |
Item 6. | Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer. |
CUSIP No. | 00767E102 | Schedule 13D | Page | 14 | of | 20 |
CUSIP No. | 00767E102 | Schedule 13D | Page | 15 | of | 20 |
CUSIP No. | 00767E102 | Schedule 13D | Page | 16 | of | 20 |
Item 7. | Materials to be Filed as Exhibits. |
Exhibit No. | Description | |
Exhibit 1: | Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended. | |
*Exhibit 2: | Second Amended and Restated Investor Rights Agreement by and among the Issuer and the other persons and entities party thereto, dated November 9, 2007 (Incorporated by reference to Exhibit 10.3 of the Issuer’s Registration Statement of Form S-1 (File No. 333-168721), filed with the Securities and Exchange Commission (the “SEC”) on August 10, 2010). | |
*Exhibit 3: | Form of Lock-up Agreement (Incorporated by reference to Exhibit A to the Underwriting Agreement filed as Exhibit 1.1 to Amendment No. 2 to the Issuer’s Registration Statement on Form S-1 (File No. 333-168721), filed with the SEC on October 7, 2010). |
* | Incorporated by reference. |
CUSIP No. | 00767E102 | Schedule 13D | Page | 17 | of | 20 |
Advent Healthcare and Life Sciences III Limited Partnership | ||||
Advent Healthcare and Life Sciences III A Limited Partnership | ||||
By: | AHLS III GP Limited Partnership, General Partner | |||
By: | Advent International LLC, General Partner | |||
By: | Advent International Corporation, Manager | |||
By: | Jarlyth H. Gibson, Compliance Officer* |
Advent Partners HLS III Limited Partnership | ||||
By: | Advent International Corporation, General Partner | |||
By: | Jarlyth H. Gibson, Compliance Officer* |
AHLS III GP Limited Partnership | ||||
By: | Advent International LLC, General Partner | |||
By: | Advent International Corporation, Manager | |||
By: | Jarlyth H. Gibson, Compliance Officer* |
Advent International LLC | ||||
By: | Advent International Corporation, Manager | |||
By: | Jarlyth H. Gibson, Compliance Officer* |
Advent International Corporation | ||||
By: | Jarlyth H. Gibson, Compliance Officer* |
* | For all of the above: |
/s/ Jarlyth H. Gibson | ||||
Jarlyth H. Gibson, Compliance Officer |
CUSIP No. | 00767E102 | Schedule 13D | Page | 18 | of | 20 |
Position with | Principal | |||
Advent International | Occupation | |||
Name | Corporation | (if different) | ||
Peter A. Brooke | Chairman | |||
Thomas H. Lauer | Senior Vice President Managing Partner Chief Operating Officer Executive Officers’ Committee Member | |||
Richard F. Kane | Senior Vice President of Operations and Business Development Managing Director Chief Compliance Officer Assistant Secretary | |||
Eileen Sivolella | Senior Vice President Managing Director Chief Financial Officer Treasurer Assistant Secretary | |||
Andrew D. Dodge | Vice President Legal Counsel Assistant Compliance Officer Secretary | |||
Jarlyth H. Gibson | Compliance Officer | |||
Ernest G. Bachrach | Executive Officers’ Committee Member | |||
Humphrey W. Battcock | Executive Officers’ Committee Member | |||
Ralf Huep | Executive Officers’ Committee Member | |||
David M. Mussafer | Director Executive Officers’ Committee Member | |||
William C. Schmidt | Executive Officers’ Committee Member | |||
Steven M. Tadler | Director Executive Officers’ |
CUSIP No. | 00767E102 | Schedule 13D | Page | 19 | of | 20 |
Position with | Principal | |||
Advent International | Occupation | |||
Name | Corporation | (if different) | ||
Committee Member | ||||
John F. Brooke | Director | General Partner of Brooke Private Equity | ||
Mark Hoffman | Director | Chairman of Cambridge Research Group |